leadf
logo-loader
viewBionomics Ltd

Bionomics completes Phase 2 of MODULATE combination clinical trial for colorectal cancer

The MODULATE trial is evaluating new experimental approaches to immunotherapy treatment in colorectal cancer patients.

Bionomics Ltd -  Bionomics completes treatment in Phase 2 of Modulate clinical trial for colorectal cancer
Trial results will be ready in Q2 2021, ahead of the previously announced timeline of early 2023.

Bionomics Ltd (ASX:BNO) (OTCMKTS:BNOEF) (FRA:B1N) has completed the MODULATE clinical trial, an experimental phase 2 trial of its drug candidate BNC105 in combination with Bristol Myers Squibb’s (NYSE:BMY) nivolumab, in patients with metastatic colorectal cancer.

The trial sponsor, the Australasian Gastro-Intestinal Trials Group (AGITG), is expecting that results will be ready in the second quarter of 2021, which is ahead of the previously announced timeline for topline data of early 2023.

Bionomics executive chairman Dr Errol De Souza said: “We thank AGITG, the trial sponsor, and the patients who participated in the study, and look forward to reporting the topline data in Q2 2021.”

The MODULATE trial

AGITG is conducting the MODULATE trial to evaluate new experimental approaches to immunotherapy treatment in colorectal cancer patients.

In one arm of the trial, it is investigating whether Bionomics’ drug candidate BNC105, a vascular disrupting agent, combined with nivolumab, a PD-1 (programmed death-1) immune checkpoint inhibitor, can be used to treat advanced colorectal cancer patients who have exhausted other treatment options.

A second group of patients are receiving nivolumab in combination with a Signal Transduction Activator of Transcription (STAT3) inhibitor.

Bionomics is a global, clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates.

Quick facts: Bionomics Ltd

Price: 0.315 AUD

ASX:BNO
Market: ASX
Market Cap: $231.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Lithium Australia's Envirostream boosting capacity for its battery recycling

Andrew Mackenzie, managing director of Lithium Australia NL (ASX:LIT) (OTCMKTS:LMMFF) (FRA:3MW) subsidiary Envirostream, discusses with Proactive's Andrew Scott the national stewardship scheme for managing end of life batteries and the potential impact it will have on the business as well as...

20 minutes ago

2 min read